NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
October 11, 2005 • Volume 2 / Number 39 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

Adjuvant Breast Cancer Therapy for Premenopausal Women

Name of the Trial
Phase III Randomized Study of Ovarian Function Suppression in Combination with Tamoxifen versus Ovarian Function Suppression in Combination with Exemestane versus Tamoxifen Alone in Premenopausal Women with Endocrine-Responsive Breast Cancer (IBCSG-24-02). See the protocol summary at http://cancer.gov/clinicaltrials/IBCSG-24-02.

Dr. Gini Fleming Study Chairs
Dr. Gini Fleming, North American Breast Intergroup; Dr. Prudence Francis, Breast International Group

Why Is This Trial Important?
Many women with breast cancer have tumors that grow in response to the female hormone estrogen (endocrine-responsive tumors). The drug tamoxifen has been used to treat endocrine-responsive breast cancer in both premenopausal and postmenopausal women.

Recently, a new class of drugs called aromatase inhibitors was shown to improve disease-free survival in postmenopausal women with endocrine-responsive cancers. However, aromatase inhibitors are not effective in premenopausal women because their ovaries are still producing estrogen.

In this trial, researchers will study three groups of premenopausal women with endocrine-responsive breast cancer. Menopause will be induced in two of the groups; one group will be treated with tamoxifen, the other with the aromatase inhibitor exemestane. Menopause will not be induced in the third group, which will be treated with tamoxifen. The researchers hope to determine which treatment approach is most effective in preventing breast cancer recurrence in premenopausal women.

"Young women with endocrine-responsive breast cancer have a high risk for recurrence if not treated with antihormone therapy," said Dr. Fleming. "We are trying to explore ways to improve that therapy for these patients."

Who Can Join This Trial?
Researchers seek to enroll 3,000 premenopausal women diagnosed with breast cancer who have had their tumors surgically removed. See the list of eligibility criteria at http://www.cancer.gov/clinicaltrials/IBCSG-24-02.

Where Is This Trial Taking Place?
Study sites in the United States are recruiting patients for this trial. See the list of sites at http://www.cancer.gov/clinicaltrials/IBCSG-24-02.

Contact Information
See the list of study contacts at http://www.cancer.gov/clinicaltrials/IBCSG-24-02 or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The toll-free call is confidential.


An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.